SCHEMBL16694607

SCHEMBL16694607

Cc1cc(C)cc(-c2cncc(C=O)c2N2CCC(NC(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SSTR2 P30874 9/20 0.46
▸ KCNH2 Q12809 7/20 0.45
▸ CKS1B P61024 1/20 0.44
▸ SKP1 P63208 1/20 0.44
▸ SKP2 Q13309 1/20 0.44
▸ SYK P43405 2/20 0.43
▸ RET P07949 1/20 0.40
▸ PIM1 P11309 1/20 0.37
▸ PIM3 Q86V86 1/20 0.37
▸ PIM2 Q9P1W9 1/20 0.37
▸ NPY5R Q15761 1/20 0.37
▸ OPRM1 P35372 1/20 0.37
▸ OPRD1 P41143 1/20 0.37
▸ OPRK1 P41145 1/20 0.37
▸ OGFRL1 Q5TC84 1/20 0.37
▸ SUV39H2 Q9H5I1 2/20 0.37
▸ PDE10A Q9Y233 1/20 0.36
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29653459 0.94 SYK (0.47) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL15605619 0.92 SSTR2 (0.45) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16694749 0.87 SSTR2 (0.50) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16694606 0.86 SSTR2 (0.52) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16694680 0.85 SSTR2 (0.48) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16694507 0.85 SSTR2 (0.52) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16694413 0.83 SSTR2 (0.43) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16694809 0.83 SSTR2 (0.69) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16695039 0.82 SSTR2 (0.65) SSTR2KCNH2CKS1BSKP1SKP2
SCHEMBL16694916 0.82 SSTR2 (0.46) SSTR2KCNH2CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194775-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO., LTD. (JP) 2018-07-12 — — US disclosed
US-9975904-B2 Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes ONO PHARMACEUTICAL CO., LTD. (JP) 2018-05-22 — — US disclosed
US-20170183359-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO., LTD. (JP) 2017-06-29 — — US disclosed
US-9630976-B2 Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes ONO PHARMACEUTICAL CO., LTD. (JP) 2017-04-25 — — US disclosed
US-20150232478-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO., LTD. (JP) 2015-08-20 — — US disclosed
EP-2871179-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES ONO Pharmaceutical Co., Ltd. (JP) 2015-05-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183359-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES SSTR2, SSTR1, SSTR3 SSTR2 1/4885KCNH2 3384/4885CKS1B 4744/4885
US-20150232478-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES SSTR2, SSTR1, SSTR3 SSTR2 1/4885KCNH2 3149/4885CKS1B 4734/4885
US-20180194775-A1 COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES SSTR2, SSTR1, SSTR3 SSTR2 1/4885KCNH2 3384/4885CKS1B 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback